Paclitaxel and docetaxel in breast and ovarian cancer

Drug and Therapeutics Bulletin

Volumn 35, Issue 6, 1997, Pages 43-46

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL;

ALOPECIA; ANEMIA; ARTHRALGIA; BREAST CARCINOMA; BREAST METASTASIS; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; SEPSIS; SHORT SURVEY; VOMITING;

EID: 0030753240     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1997.35643     Document Type: Short Survey

References (34)

1. Paclitaxel for ovarian cancer. DTB 1994; 32: 41-2.
2. Cisplatin or carboplatin for ovarian and testicular cancer? DTB 1994; 32: 62-3.
3. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
4. Einzig Al, Wiemik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
5. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
6. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
7. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10.
8. Gore ME, Preston N, A'Hern RP et al. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 1995; 71: 1308-10.
9. Gore ME, Levy V, Rustin G et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-9.
10. Kohn EC, Sarosy G, Bicher A et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24
11. Colombo N, Marzola M, Parma G et al. Paclitaxel vs. CAP (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study. Proc Am Soc Clin Oncol 1996; 15: 279 [abstract].
12. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 1991; 9 389-93.
13. Francis P, Hakes T, Schneider J et al. Phase II study of docetaxel (Taxotere®) in advanced platinum-refractory ovarian cancer (CA). Proc Am Soc Clin Oncol 1994; 13: 260 [abstract].
14. Kaye SB, Piccart M, Aapro M, Kavanagh J, on behalf of the EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center, USA Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 1995; 31A (suppl 4): S14-7.
15. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
16. Peretz T, Sulkes A, Chollet P et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 1995; 31A (suppl 5): S75 [abstract].
17. Reichman BS, Seidman AD, Crown JPA et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
18. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996; 23 (suppl 1): 4-9.
19. Dieras V, Marty M, Tubiana N et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995; 22 (suppl 8): 33-9.
20. Nabholtz J-M, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
21. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 1994; 21 (suppl 8): 29-33.
22. Wilson WH, Berg SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
23. Chan S, Friedrichs K, Noel D et al A randomized phase III study of Taxotere® (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen, preliminary results. Proc Am Soc Clin Oncol 1997; 16: 154a [abstract].
24. Nabholtz J-M, Thuerlimann B, Bezwoda WR et al. Taxotere® (T) versus mitomycin C + vinblastine (MV) in patients (pts) with metastatic breast cancer (MBC) who have failed an anthracycline containing regimen: preliminary results of a randomized phase III study. Proc Am Soc Clin Oncol 1997; 16: 148a [abstract].
25. Hudis CA, Seidman AD, Crown JPA et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65.
26. Fumoleau P, Chevallier B, Kerbrat P et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996, 7: 165-71.
27. ten Bokkel Huinink WW, Prove AM, Piccart M et al. A phase H trial with docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-32.
28. Ravdin PM, Burrris III HA, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
29. Valero V, Holmes FA, Walters RS et al. Phase II tril of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
30. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
31. Taxol™(paclitaxel) summary of product characteristics. Bristol-Myers Squibb Pharmaeuticals Ltd.
32. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequences of Taxol and cisplatin. a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
33. Taxotere? (docetaxel) summary of product characteristics. RhônePoulenc Rorer.
34. Lemenager M, Genouville C, Bessa EH, Bonneterre J. Docetaxel-induced alopecia can be prevented. Lancet 1995; 346: 371-2 [letter].